Jefferies analyst David Windley lowered the firm’s price target on Elevance Health (ELV) to $391 from $395 and keeps a Buy rating on the shares. The firm adjusted estimates among its managed care coverage following a deep dive into health insurance plans offered on the Health Insurance Exchange.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- ELV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- One in seven enrollees in ACA plans failed to make payments this year, WSJ says
- Elevance Health price target lowered to $375 from $390 at Truist
- Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls
- Elevance Health initiated with an In Line at Evercore ISI